Loading organizations...
Key people at ORI Healthcare Fund.
ORI Healthcare Fund, managed by Hong Kong-based ORI Capital, is a venture capital fund investing in early-stage biotechnology and healthcare companies globally. The fund strategically deploys capital into innovative diagnostics, drug delivery, and therapeutics across diverse disease areas. It focuses on identifying and nurturing disruptive scientific advancements in the life sciences sector.
The fund was founded in 2015 by Simone Song, who serves as a Founding Partner. Song's insight centered on building a dedicated investment platform to support the translation of fundamental scientific research into impactful healthcare solutions. Her experience guides the fund's commitment to backing promising ventures in the biotechnology landscape.
ORI Healthcare Fund seeks to partner with innovative biotechnology and healthcare companies requiring early-stage capital and strategic guidance. Its vision is to accelerate the development of life-saving treatments and improve patient outcomes worldwide. The fund endeavors to be a pivotal force in driving forward medical innovation.
Key people at ORI Healthcare Fund.
ORI Healthcare Fund has 4 tracked investments across 4 companies. The latest tracked deal is $47.0M Series D in CG Oncology in December 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 10, 2020 | CG Oncology | $47.0M Series D | Mutsuo Kanzawa | Camford Capital, Perseverance Capital Management |
| May 12, 2020 | Pillar Biosciences | $29.7M Series C | ORI Healthcare Fund | — |
| Nov 30, 2017 | Semma Therapeutics | $114.0M Series B | Kevin Raidy, Daniel Auerbach | 6 Dimensions Capital, ARCH Venture Partners, F Prime Capital, JDRF T1D Fund, Medtronic, MPM Capital, Novartis, Sinopharm Capital, WU Capital |
| Nov 16, 2017 | Arterys | $30.0M Series B | Temasek | DNA Capital, Emergent Medical Partners, Fosun 复星, GE Ventures, NewYork Presbyterian Hospital, TOM Thornton, Rafael Torres |
